Drugs / SP059
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01389687 | Jul 2011 → Jan 2012 | poliomyelitis | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SP059 | “The aim of the study is to assess the immunogenicity and safety of SP059 as a three-dose primary and booster vaccination in Japanese infants aged 3 through 68 months.” NCT01389687 ↗ |
| Route | Subcutaneous | “0.5 mL, Subcutaneous” NCT01389687 ↗ |